{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:54:39Z","timestamp":1788188079795,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR302776"],"award-info":[{"award-number":["NIHR302776"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/X015017\/1"],"award-info":[{"award-number":["MR\/X015017\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.rmed.2024.107882","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T16:13:29Z","timestamp":1732292009000},"page":"107882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal study"],"prefix":"10.1016","volume":"236","author":[{"given":"Connett","family":"Gj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maguire","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larcombe","family":"Tc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scanlan","family":"N","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0087-941X","authenticated-orcid":false,"given":"Shinde","family":"Ss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthukumarana","family":"T","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bevan","family":"A","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keogh","family":"Rh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Legg","family":"Jp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2024.107882_bib1","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2024.107882_bib2","series-title":"UK Cystic Fibrosis Registry Annual Data Report 2022","year":"2023"},{"key":"10.1016\/j.rmed.2024.107882_bib3","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1056\/NEJMoa2100665","article-title":"VX18-445-104 study group, triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes. Reply","volume":"385","author":"Barry","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107882_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107882_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107882_bib6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/thoraxjnl-2020-215556","article-title":"Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year study","volume":"76","author":"Mitchell","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2024.107882_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s40545-021-00385-w","article-title":"Estimating proportion of days covered (PDC) using real-world online medicine suppliers' datasets","volume":"14","author":"Prieto-Merino","year":"2021","journal-title":"J. Pharm. Policy. Pract."},{"key":"10.1016\/j.rmed.2024.107882_bib8","series-title":"A Language and Environment for Statistical Computing","year":"2022"},{"key":"10.1016\/j.rmed.2024.107882_bib9","first-page":"1","article-title":"The R package geepack for generalized estimating equations","volume":"15","author":"H\u00f8jsgaard","year":"2006","journal-title":"J. Stat. Software"},{"key":"10.1016\/j.rmed.2024.107882_bib10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of Elexacaftor\/Tezacaftor\/Ivacaftor on annual rate of lung function decline in people with Cystic Fibrosis","volume":"22","author":"Lee","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2024.107882_bib11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"VX17-445-102 Study Group, Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2024.107882_bib12","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor\/tezacaftor\/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2024.107882_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"PROMISE study group, clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2024.107882_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1176815","article-title":"Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis","volume":"14","author":"Olivier","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.rmed.2024.107882_bib15","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"The Lancet Reg. Health \u2013 Europe"},{"key":"10.1016\/j.rmed.2024.107882_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/21556660.2021.1912352","article-title":"Adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: analysis of a national specialty pharmacy database","volume":"10","author":"Mehta","year":"2021","journal-title":"J. Drug Assess."},{"key":"10.1016\/j.rmed.2024.107882_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.rmed.2024.107882_bib18","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/ppul.24157","article-title":"Rapid therapeutic advances in CFTR modulator science","volume":"53","author":"Clancy","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2024.107882_bib19","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/ppul.23307","article-title":"A five-year retrospective analysis of adherence in cystic fibrosis","volume":"50","author":"Shakkottai","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2024.107882_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1378\/chest.13-1926","article-title":"Pulmonary medication adherence and health-care use in cystic fibrosis","volume":"146","author":"Quittner","year":"2014","journal-title":"CHEST"},{"key":"10.1016\/j.rmed.2024.107882_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-Tezacaftor-ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.rmed.2024.107882_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12931-023-02451-0","article-title":"Heterogeneity of weight gain after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis","volume":"24","author":"Gramegna","year":"2023","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2024.107882_bib23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mcna.2017.08.012","article-title":"Maintenance of lost weight and long-term management of obesity","volume":"102","author":"Hall","year":"2018","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.rmed.2024.107882_bib24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/PPA.S103649","article-title":"Weight loss intervention adherence and factors promoting adherence: a meta-analysis","volume":"10","author":"Lemstra","year":"2016","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.rmed.2024.107882_bib25","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/cid\/ciac117","article-title":"The rapid reduction of infection-related visits and antibiotic use among people with cystic fibrosis after starting elexacaftor-tezacaftor-ivacaftor","volume":"75","author":"Miller","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.rmed.2024.107882_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/antibiotics12020217","article-title":"Antibiotic resistance in patients with cystic fibrosis: past, present, and future","volume":"12","author":"Perikleous","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.rmed.2024.107882_bib27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jcf.2019.07.008","article-title":"The impact of CFTR modulator therapies on CF airway microbiology","volume":"19","author":"Rogers","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2024.107882_bib28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijid.2023.11.013","article-title":"Registry Working Group of the German CF Registry, Use of elexacaftor\/tezacaftor\/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis","volume":"139","author":"Dittrich","year":"2024","journal-title":"Int. J. Infect. Dis."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124003573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611124003573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T22:01:17Z","timestamp":1738879277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611124003573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"alternative-id":["S0954611124003573"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107882","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2024.107882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107882"}}